Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Magnesium supplementation therapy to prevent cisplatin-induced acute nephrotoxicity in pediatric cancer: A protocol for a randomized phase 2 trial.

Makimoto A, Matsui M, Chin M, Koh K, Tomotsune M, Kaneko T, Morikawa Y, Yuza Y.

Contemp Clin Trials Commun. 2019 Aug 22;16:100440. doi: 10.1016/j.conctc.2019.100440. eCollection 2019 Dec.

2.

Registration-directed phase 1/2 trial of irinotecan for pediatric solid tumors.

Makimoto A, Mugishima H, Taga T, Ishida Y, Nagatoshi Y, Ida K, Kumagai M, Kimura T, Ohashi Y, Kaneko M.

Pediatr Int. 2019 May;61(5):453-458. doi: 10.1111/ped.13826. Epub 2019 May 14.

PMID:
30859690
3.

Kidney-protective Effect of Magnesium Supplementation in Cisplatin-containing Chemotherapy for Pediatric Cancer: A Retrospective Study.

Matsui M, Saito Y, Yamaoka S, Yokokawa Y, Morikawa Y, Makimoto A, Yuza Y.

J Pediatr Hematol Oncol. 2018 Jul;40(5):379-381. doi: 10.1097/MPH.0000000000001159.

PMID:
29683958
4.

Treatment outcome of children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group (TCCSG) Study L04-16.

Takahashi H, Kajiwara R, Kato M, Hasegawa D, Tomizawa D, Noguchi Y, Koike K, Toyama D, Yabe H, Kajiwara M, Fujimura J, Sotomatsu M, Ota S, Maeda M, Goto H, Kato Y, Mori T, Inukai T, Shimada H, Fukushima K, Ogawa C, Makimoto A, Fukushima T, Ohki K, Koh K, Kiyokawa N, Manabe A, Ohara A.

Int J Hematol. 2018 Jul;108(1):98-108. doi: 10.1007/s12185-018-2440-4. Epub 2018 Mar 27.

PMID:
29589281
5.

Ground Reaction Forces During Sprinting in Unilateral Transfemoral Amputees.

Makimoto A, Sano Y, Hashizume S, Murai A, Kobayashi Y, Takemura H, Hobara H.

J Appl Biomech. 2017 Dec 1;33(6):406-409. doi: 10.1123/jab.2017-0008. Epub 2017 Nov 8.

PMID:
28605277
6.

Leg stiffness during sprinting in transfemoral amputees with running-specific prosthesis.

Sano Y, Makimoto A, Hashizume S, Murai A, Kobayashi Y, Takemura H, Hobara H.

Gait Posture. 2017 Jul;56:65-67. doi: 10.1016/j.gaitpost.2017.04.038. Epub 2017 May 4.

PMID:
28505545
7.

Significance of CD66c expression in childhood acute lymphoblastic leukemia.

Kiyokawa N, Iijima K, Tomita O, Miharu M, Hasegawa D, Kobayashi K, Okita H, Kajiwara M, Shimada H, Inukai T, Makimoto A, Fukushima T, Nanmoku T, Koh K, Manabe A, Kikuchi A, Sugita K, Fujimoto J, Hayashi Y, Ohara A.

Leuk Res. 2014 Jan;38(1):42-8. doi: 10.1016/j.leukres.2013.10.008. Epub 2013 Oct 22.

PMID:
24231528
8.

Vascular endothelial growth factor-D-mediated blockade of regulatory T cells within tumors is induced by hematopoietic stem cell transplantation.

Udagawa T, Narumi K, Suzuki K, Aida K, Miyakawa R, Ikarashi Y, Makimoto A, Chikaraishi T, Yoshida T, Aoki K.

J Immunol. 2013 Sep 15;191(6):3440-52. doi: 10.4049/jimmunol.1201454. Epub 2013 Aug 21.

9.

Anaplastic lymphoma kinase status in rhabdomyosarcomas.

Yoshida A, Shibata T, Wakai S, Ushiku T, Tsuta K, Fukayama M, Makimoto A, Furuta K, Tsuda H.

Mod Pathol. 2013 Jun;26(6):772-81. doi: 10.1038/modpathol.2012.222. Epub 2013 Jan 11.

10.

Comparison of dose intensity of vincristine, d-actinomycin, and cyclophosphamide chemotherapy for child and adult rhabdomyosarcoma: a retrospective analysis.

Kojima Y, Hashimoto K, Ando M, Yonemori K, Yamamoto H, Kodaira M, Yunokawa M, Shimizu C, Tamura K, Hosono A, Makimoto A, Fujiwara Y.

Cancer Chemother Pharmacol. 2012 Sep;70(3):391-7. doi: 10.1007/s00280-012-1920-0. Epub 2012 Jul 18.

PMID:
22806306
11.

A case of stage IV neuroblastoma treated with aggressive surgery following intensive neoadjuvant chemotherapy with autologous stem cell transplantation.

Yamamoto Y, Makimoto A.

Jpn J Clin Oncol. 2012 Apr;42(4):359. doi: 10.1093/jjco/hys044. No abstract available.

PMID:
22457363
12.

Clinical outcomes of adult and childhood rhabdomyosarcoma treated with vincristine, d-actinomycin, and cyclophosphamide chemotherapy.

Kojima Y, Hashimoto K, Ando M, Yonemori K, Hirakawa A, Kodaira M, Yunokawa M, Shimizu C, Tamura K, Katsumata N, Hosono A, Makimoto A, Fujiwara Y.

J Cancer Res Clin Oncol. 2012 Jul;138(7):1249-57. doi: 10.1007/s00432-012-1199-x. Epub 2012 Mar 23.

PMID:
22441933
13.

Syngeneic hematopoietic stem cell transplantation enhances the antitumor immunity of intratumoral type I interferon gene transfer for sarcoma.

Udagawa T, Narumi K, Goto N, Aida K, Suzuki K, Ochiya T, Makimoto A, Yoshida T, Chikaraishi T, Aoki K.

Hum Gene Ther. 2012 Feb;23(2):173-86. doi: 10.1089/hum.2011.046. Epub 2012 Jan 26.

PMID:
21958207
14.

[Phase I study of nelarabine in patients with relapsed or refractory T-ALL/T-LBL].

Horibe K, Takimoto T, Yokozawa T, Makimoto A, Kobayashi Y, Ogawa C, Ohno R, Koh N, Katsura K, Tobinai K.

Rinsho Ketsueki. 2011 Jun;52(6):406-15.

PMID:
21737993
15.

Secondary neoplasms after retinoblastoma treatment: retrospective cohort study of 754 patients in Japan.

Araki Y, Matsuyama Y, Kobayashi Y, Toyokawa S, Inoue K, Suzuki S, Makimoto A.

Jpn J Clin Oncol. 2011 Mar;41(3):373-9. doi: 10.1093/jjco/hyq201. Epub 2010 Nov 4.

PMID:
21051531
16.

Metastatic Wilms' tumor in an adolescent successfully treated with multimodal pediatric therapy.

Watanabe A, Hosono A, Makimoto A.

Pediatr Int. 2010 Oct;52(5):836-8. No abstract available.

PMID:
20925140
17.

Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation.

Momota H, Narita Y, Miyakita Y, Hosono A, Makimoto A, Shibui S.

Pediatr Blood Cancer. 2010 Sep;55(3):577-9. doi: 10.1002/pbc.22542. Erratum in: Pediatr Blood Cancer. 2011 Mar;56(3):509. Nariata, Yoshitaka [corrected to Narita, Yoshitaka].

PMID:
20658636
18.

Pharmacokinetic and pharmacodynamic investigation of irinotecan hydrochloride in pediatric patients with recurrent or progressive solid tumors.

Kimura T, Kashiwase S, Makimoto A, Kumagai M, Taga T, Ishida Y, Ida K, Nagatoshi Y, Mugishima H, Kaneko M, Barrett JS.

Int J Clin Pharmacol Ther. 2010 May;48(5):327-34.

PMID:
20420789
19.

A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome.

Kikuchi A, Kigasawa H, Tsurusawa M, Kawa K, Kikuta A, Tsuchida M, Nagatoshi Y, Asami K, Horibe K, Makimoto A, Tsukimoto I.

Int J Hematol. 2009 Nov;90(4):492-500. doi: 10.1007/s12185-009-0402-6. Epub 2009 Aug 22.

PMID:
19701676
20.

Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma.

Tateishi U, Hosono A, Makimoto A, Nakamoto Y, Kaneta T, Fukuda H, Murakami K, Terauchi T, Suga T, Inoue T, Kim EE.

Ann Nucl Med. 2009 Feb;23(2):155-61. doi: 10.1007/s12149-008-0219-z. Epub 2009 Feb 19.

PMID:
19225939
21.

Segregated graft-versus-tumor effect between CNS and non-CNS lesions of Ewing's sarcoma family of tumors.

Hosono A, Makimoto A, Kawai A, Takaue Y.

Bone Marrow Transplant. 2008 Jun;41(12):1067-8. doi: 10.1038/bmt.2008.26. Epub 2008 Mar 10. No abstract available.

PMID:
18332914
22.

Accuracy of 18F fluorodeoxyglucose positron emission tomography/computed tomography in staging of pediatric sarcomas.

Tateishi U, Hosono A, Makimoto A, Sakurada A, Terauchi T, Arai Y, Imai Y, Kim EE.

J Pediatr Hematol Oncol. 2007 Sep;29(9):608-12.

PMID:
17805034
23.

Prediction of response and prognostic factors for Ewing family of tumors in a low incidence population.

Yonemori K, Yamaguchi U, Kaneko M, Uno H, Takeuchi M, Ando M, Fujiwara Y, Hosono A, Makimoto A, Hasegawa T, Yokoyama R, Nakatani F, Kawai A, Beppu Y, Chuman H.

J Cancer Res Clin Oncol. 2008 Mar;134(3):389-95. Epub 2007 Aug 9.

PMID:
17687565
24.

Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen.

Maruyama D, Fukuda T, Kato R, Yamasaki S, Usui E, Morita-Hoshi Y, Kim SW, Mori S, Heike Y, Makimoto A, Tajima K, Tanosaki R, Tobinai K, Takaue Y.

Biol Blood Marrow Transplant. 2007 Aug;13(8):932-41. Epub 2007 May 29.

25.

Primary bone lymphoma: a new and detailed characterization of 28 patients in a single-institution study.

Maruyama D, Watanabe T, Beppu Y, Kobayashi Y, Kim SW, Tanimoto K, Makimoto A, Kagami Y, Terauchi T, Matsuno Y, Tobinai K.

Jpn J Clin Oncol. 2007 Mar;37(3):216-23.

PMID:
17472971
26.

[Ewing sarcoma].

Hamanoue S, Makimoto A.

Gan To Kagaku Ryoho. 2007 Feb;34(2):175-80. Japanese.

PMID:
17301523
27.

Nutritional support for patients suffering from intestinal graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Imataki O, Nakatani S, Hasegawa T, Kondo M, Ichihashi K, Araki M, Ishida T, Kim SW, Mori S, Fukuda T, Tobinai K, Tanosaki R, Makimoto A, Takaue Y.

Am J Hematol. 2006 Oct;81(10):747-52.

28.

Utility of immunohistochemical analysis for cyclo-oxygenase 2 in the differential diagnosis of osteoblastoma and osteosarcoma.

Hosono A, Yamaguchi U, Makimoto A, Endo M, Watanabe A, Shimoda T, Kaya M, Matsumura T, Sonobe H, Kusumi T, Yamaguchi T, Hasegawa T.

J Clin Pathol. 2007 Apr;60(4):410-4. Epub 2006 Jul 5.

29.

Coincidental outbreak of methicillin-resistant Staphylococcus aureus in a hematopoietic stem cell transplantation unit.

Imataki O, Makimoto A, Kato S, Bannai T, Numa N, Nukui Y, Morisawa Y, Ishida T, Kami M, Fukuda T, Mori S, Tanosaki R, Takaue Y.

Am J Hematol. 2006 Sep;81(9):664-9.

30.
31.

[Treatment for Ewing's sarcoma family of tumors in children].

Mugishima H, Chin M, Yokoyama R, Makimoto A.

Nihon Geka Gakkai Zasshi. 2005 Jul;106(7):437-43. Review. Japanese.

PMID:
16045188
32.

Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases.

Sato O, Wada T, Kawai A, Yamaguchi U, Makimoto A, Kokai Y, Yamashita T, Chuman H, Beppu Y, Tani Y, Hasegawa T.

Cancer. 2005 May 1;103(9):1881-90.

33.

A multidisciplinary treatment strategy that includes high-dose chemotherapy for metastatic retinoblastoma without CNS involvement.

Matsubara H, Makimoto A, Higa T, Kawamoto H, Sakiyama S, Hosono A, Takayama J, Takaue Y, Murayama S, Sumi M, Kaneko A, Ohira M.

Bone Marrow Transplant. 2005 Apr;35(8):763-6.

PMID:
15750608
34.

A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease.

Hori A, Kanda Y, Goyama S, Onishi Y, Komeno Y, Mitani K, Kishi Y, Ogawa S, Imataki O, Chiba S, Kojima R, Hamaki T, Sakiyama M, Kami M, Makimoto A, Tanosaki R, Takaue Y, Hirai H; Japan Hematology and Oncology Clinical Study Group.

Transplantation. 2005 Feb 15;79(3):372-4.

PMID:
15699774
35.

Reduced-intensity hematopoietic stem cell transplantation (RIST) for solid malignancies.

Kami M, Makimoto A, Heike Y, Takaue Y.

Jpn J Clin Oncol. 2004 Dec;34(12):707-16. Review.

PMID:
15640500
36.

Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1-year follow-up.

Nakagawa T, Kami M, Hori A, Kim SW, Murashige N, Hamaki T, Kishi Y, Fujimoto H, Matsuoka N, Okajima E, Komiyama M, Tobisu K, Wakayama T, Uike N, Tajima K, Makimoto A, Mori S, Tanosaki R, Takaue Y, Kakizoe T.

Exp Hematol. 2004 Jul;32(7):599-606.

PMID:
15246155
37.
39.

Urgent need for a validated tumor response evaluation system for use in immunotherapy.

Hori A, Kami M, Kim SW, Murashige N, Sakiyama M, Kojima R, Hamaki T, Makimoto A, Miyakoshi S, Masuo S, Taniguchi S, Kunitoh H, Takaue Y.

Bone Marrow Transplant. 2004 Jan;33(2):255-6; author reply 257-8. No abstract available.

PMID:
14676774
40.

Late hemorrhagic cystitis after reduced-intensity hematopoietic stem cell transplantation (RIST).

Yamamoto R, Kusumi E, Kami M, Yuji K, Hamaki T, Saito A, Murasgihe N, Hori A, Kim SW, Makimoto A, Ueyama J, Tanosaki R, Miyakoshi S, Mori S, Morinaga S, Heike Y, Taniguchi S, Masuo S, Takaue Y, Mutou Y.

Bone Marrow Transplant. 2003 Dec;32(11):1089-95.

PMID:
14625581
41.

Cryopreservation of mobilized blood stem cells at a higher cell concentration without the use of a programmed freezer.

Kawano Y, Lee CL, Watanabe T, Abe T, Suzuya H, Okamoto Y, Makimoto A, Nakagawa R, Watanabe H, Takaue Y.

Ann Hematol. 2004 Jan;83(1):50-4. Epub 2003 Nov 13.

PMID:
14615914
42.

[Mini-transplantation for solid tumors].

Kim SW, Makimoto A.

Nihon Rinsho. 2003 Sep;61(9):1613-8. Review. Japanese.

PMID:
14515733
43.

Induction of graft-versus-autoimmune (GVA) disease effect against refractory psoriasis by complete donor-type chimerism and graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Kojima R, Kami M, Kim SW, Murashige N, Kishi Y, Hori A, Imataki O, Hamaki T, Sakiyama M, Masuo S, Fujisawa Y, Makimoto A, Heike Y, Tanosaki R, Takaue Y.

Bone Marrow Transplant. 2003 Aug;32(4):439-42.

PMID:
12900783
44.

Antithymocyte globulin affects the occurrence of acute and chronic graft-versus-host disease after a reduced-intensity conditioning regimen by modulating mixed chimerism induction and immune reconstitution.

Nakai K, Mineishi S, Kami M, Saito T, Hori A, Kojima R, Imataki O, Hamaki T, Yoshihara S, Ohnishi M, Kim SW, Ando T, Fumitoh A, Kanda Y, Makimoto A, Tanosaki R, Kanai S, Heike Y, Ohnishi T, Kawano Y, Wakasugi H, Takaue Y.

Transplantation. 2003 Jun 27;75(12):2135-43.

PMID:
12829926
45.

Adult neuroblastoma: radiologic and clinicopathologic features.

Tateishi U, Hasegawa T, Makimoto A, Moriyama N.

J Comput Assist Tomogr. 2003 May-Jun;27(3):321-6.

PMID:
12794593
46.

Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies.

Mineishi S, Kanda Y, Saito T, Nakai K, Makimoto A, Kami M, Tanosaki R, Wakasugi H, Tobinai K, Takaue Y.

Br J Haematol. 2003 Apr;121(2):296-303.

PMID:
12694252
47.

Life-threatening hypothyroidism associated with administration of cyclosporine in a patient treated with reduced-intensity hematopoietic stem-cell transplantation for metastatic renal-cell carcinoma.

Imataki O, Kim SW, Kojima R, Hori A, Hamaki T, Sakiyama M, Murashige N, Satoh M, Kami M, Makimoto A, Takaue Y.

Transplantation. 2003 Mar 27;75(6):898-907. No abstract available.

PMID:
12660521
48.

Possible benefits of high-dose chemotherapy as intensive consolidation in patients with high-risk rhabdomyosarcoma who achieve complete remission with conventional chemotherapy.

Matsubara H, Makimoto A, Higa T, Kawamoto H, Takayama J, Ohira M, Yokoyama R, Beppu Y, Takaue Y.

Pediatr Hematol Oncol. 2003 Apr-May;20(3):201-10.

PMID:
12637216
49.

Successful treatment of meningoencephalitis caused by methicillin-resistant Staphylococcus aureus with intrathecal vancomycin in an allogeneic peripheral blood stem cell transplant recipient.

Matsubara H, Makimoto A, Higa T, Kawamoto H, Kanda Y, Kami M, Tanosaki R, Mineishi S, Ohira M, Takaue Y.

Bone Marrow Transplant. 2003 Jan;31(1):65-7.

PMID:
12621510
50.

Primary cutaneous aspergillosis caused by Aspergillus ustus following reduced-intensity stem cell transplantation.

Nakai K, Kanda Y, Mineishi S, Hori A, Chizuka A, Niiya H, Tanimoto T, Ohnishi M, Kami M, Makimoto A, Tanosaki R, Matsuno Y, Yamazaki N, Tobinai K, Takaue Y.

Ann Hematol. 2002 Oct;81(10):593-6. Epub 2002 Sep 24.

PMID:
12424542

Supplemental Content

Loading ...
Support Center